Additional drug resistance for Mycobacterium tuberculosis during turnaround time for drug-susceptibility testing in China: A multicenter observational cohort study

•One third developed extra drug resistance within turnaround time for DST results.•One fourth of MDR Mtb acquired PZA/EMB resistance within turnaround time for DST.•Exogenous reinfection played a ponderous role in the drug resistance acquisition. Although phenotypic drug susceptibility testing (DST)...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:International journal of infectious diseases Jg. 108; S. 81 - 88
Hauptverfasser: Zhu, Jiahui, Bao, Ziwei, Xie, Yan, Werngren, Jim, Hu, Yi, Davies Forsman, Lina, Bruchfeld, Judith, Hoffner, Sven
Format: Journal Article
Sprache:Englisch
Veröffentlicht: Canada Elsevier Ltd 01.07.2021
Elsevier
Schlagworte:
Additional drug resistance
Drug-susceptibility testing
Exogenous reinfection
Mixed infection
Turnaround time
Mixed infection
Turnaround time
Drug-susceptibility testing
Additional drug resistance
Exogenous reinfection
ISSN:1201-9712, 1878-3511, 1878-3511
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:•One third developed extra drug resistance within turnaround time for DST results.•One fourth of MDR Mtb acquired PZA/EMB resistance within turnaround time for DST.•Exogenous reinfection played a ponderous role in the drug resistance acquisition. Although phenotypic drug susceptibility testing (DST) of Mycobacterium tuberculosis (Mtb) takes up to 6–8 weeks, little is known about how drug susceptibility is affected during this period. We performed a prospective cohort study to investigate the development of drug resistance (DR) during turnaround time (TAT), including 359 pulmonary tuberculosis (PTB) patients with a baseline DST result of an Mtb isolate collected at TB diagnosis and a follow-up DST result of an Mtb isolate collected when baseline DST result was available between 2013 and 2018. Whole-genome sequencing (WGS) was used to differentiate between acquired drug resistance, exogenous reinfection, and mixed infection. Among the studied patients, during TAT for DST, 116 (32.3%) developed DR to four first-line drugs (rifampicin, isoniazid, pyrazinamide, ethambutol). Among 116 pairs of isolates included for WGS, 21 pairs were classified as acquired drug resistance with single nucleotide polymorphisms (SNPs) differences less than 12. Four pairs with an intermediate SNPs differences displayed minor differences in related genotypes and were assessed as mixed infection. The remaining 91 pairs had high SNPs differences consistent with exogenous reinfection. The exogenous reinfection of drug-resistant strains played a vital role in the development of DR of Mtb isolates during TAT for DST, highlighting the need for both rapid DST methods and improved infection control.
Bibliographie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Undefined-3
ISSN:1201-9712
1878-3511
1878-3511
DOI:10.1016/j.ijid.2021.04.027